Washburn Capital Management Inc. Acquires 1,235 Shares of iShares Biotechnology ETF (NASDAQ:IBB)

Washburn Capital Management Inc. raised its holdings in shares of iShares Biotechnology ETF (NASDAQ:IBBGet Rating) by 61.9% in the second quarter, Holdings Channel.com reports. The firm owned 3,230 shares of the financial services provider’s stock after purchasing an additional 1,235 shares during the period. Washburn Capital Management Inc.’s holdings in iShares Biotechnology ETF were worth $380,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in IBB. Bank of America Corp DE increased its stake in shares of iShares Biotechnology ETF by 4.8% during the first quarter. Bank of America Corp DE now owns 12,331,586 shares of the financial services provider’s stock valued at $1,606,806,000 after purchasing an additional 568,232 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in shares of iShares Biotechnology ETF by 49.9% during the first quarter. Goldman Sachs Group Inc. now owns 1,568,159 shares of the financial services provider’s stock valued at $204,332,000 after purchasing an additional 521,820 shares in the last quarter. Citigroup Inc. increased its stake in shares of iShares Biotechnology ETF by 23.6% during the first quarter. Citigroup Inc. now owns 1,973,585 shares of the financial services provider’s stock valued at $257,158,000 after purchasing an additional 376,498 shares in the last quarter. Hackensack Meridian Health Inc. bought a new position in shares of iShares Biotechnology ETF during the first quarter valued at approximately $29,710,000. Finally, UBS Group AG grew its holdings in shares of iShares Biotechnology ETF by 10.9% during the first quarter. UBS Group AG now owns 2,005,796 shares of the financial services provider’s stock valued at $261,355,000 after buying an additional 196,343 shares during the last quarter. Institutional investors own 60.42% of the company’s stock.

iShares Biotechnology ETF Price Performance

Shares of IBB traded down $2.43 on Friday, hitting $114.30. 68,831 shares of the stock traded hands, compared to its average volume of 1,872,065. The business has a 50 day simple moving average of $125.20 and a 200 day simple moving average of $122.41. iShares Biotechnology ETF has a one year low of $104.29 and a one year high of $174.45.

iShares Biotechnology ETF Company Profile

(Get Rating)

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

See Also

Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBBGet Rating).

Institutional Ownership by Quarter for iShares Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.